North America, followed by the Europe, dominates the global market for kidney fibrosis due to large number of aging population and better healthcare facilities available in the region. In addition, there is high prevalence of kidney diseases in the region. According to The Centers for Disease Control and Prevention (CDC), a public health institute in 2014, in the U.S., it is estimated that more than 20 million people are suffering from chronic kidney disease. Asia is expected to show high growth rate in the next few years in global kidney fibrosis treatment market. China and India are expected to be the fastest kidney fibrosis market in Asia region. Some of the key driving forces for kidney fibrosis market in emerging countries are increasing R&D investment, large pool of patients, rising government funding and growing level of awareness.
View Sample Report @ http://www.persistencemarketresearch.com/samples/3102
Diseases such as obesity accelerate the incidence of kidney fibrosis. In addition, habits such smoking also adds to increment in incidence of kidney fibrosis. Increasing patient pool, rising awareness about treatment of kidney diseases and government funding are some of the key factors driving the kidney fibrosis market. In addition, introduction of safer and effective therapeutics for the treatment of kidney fibrosis is driving the market. However, high cost involved and no success for all the cases is restraining the kidney fibrosis market.
Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/3102
Introduction of the concept of personalized medicines, mono-therapeutic approaches or combination of therapies are expected to offer good opportunities for kidney fibrosis market. In addition, introduction statins for, which are related to lowering of lipid content, thus expected to be an efficient treatment for kidney scarring. Growing demographics and economies in the developing countries such as India and China in Asia and other countries in South East Asia, Latin America and Middle East are expected to offer high growth in kidney fibrosis treatment market. One of the major trends that have been observed in kidney fibrosis treatment market includes various pharmaceutical and biotechnology companies involved in R&D of some novel medications for the treatment of kidney fibrosis. Some of the key companies dealing in kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Pfizer, Inc, La Jolla Pharmaceutical Company, Merck & Co., InterMune, Inc. and Galectin Therapeutics, Inc. Other companies dealing the kidney fibrosis treatment market which have significant presence are Genzyme Corporation, ProMetic Life Sciences Inc. and BioLineRx, Ltd.
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
Persistence Market Research Pvt. Ltd
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353